April 15th 2024
C3TI will promote CDER’s clinical trial innovation activities both internally and externally.
Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures
April 28th 2023clonoSEQ Assay is authorized by FDA for MRD assessment in lymphoid malignancies and is highly accurate, sensitive, and standardized compared to other technologies used for disease burden assessment.
AMB-05X Receives EMA PRIME Designation for Treatment of Tenosynovial Giant Cell Tumor
January 20th 2023The efficacy data across multiple clinical endpoints and a favorable safety profile support the potential of AMB-05X as a best-in-class therapy for the treatment of TGCT regardless of surgical resectability.
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development
Extrapolating data from adult clinical trials to a pediatric population is a proven method to avoid unnecessary pediatric clinical trials. Representatives of the Pediatric Working Group of the IQ Consortium share case studies that demonstrate how adult clinical trial data can be used to support the dose selection and regimen—or waive the need for a placebo control arm—for pediatric studies.